Helen X Chen

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al. · Nature Medicine · 2004 · 2K citations · Full text

Medicine, Cancer Biology, Oncology +17

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 232 citations · Full text

Medicine, Oncology, Radiation Oncology +14

A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.

Helen X Chen, John L. Marshall, Elizabeth Ness et al. · PubMed · 2000 · 63 citations

Medicine, Pharmacokinetics, Pharmacology +14

Ocular adverse events in PD-1 and PD-L1 inhibitors

James H. Murray, Howard Streicher, Elad Sharon et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 2021 · 47 citations · Full text

Medicine, Oncology, Pharmacology +15

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

Naiyer A. Rizvi, Foluso O. Ademuyiwa, Z. Alexander Cao et al. · Journal for ImmunoTherapy of Cancer · 2023 · 42 citations · Full text

Medicine, Immunology, Oncology +17